The recent advent of inhibitors of immune-checkpoints [cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death-1 (PD-1)], and of novel targeted therapies drastically improved survival expectations for advanced melanoma patients [3]. This evidence concerns the gene PDCD1 and melanoma.